SGLT-2 Inhibitors Are Most Strongly Associated with Euglycemic DKA
SGLT-2 inhibitors are the antidiabetic class most strongly associated with euglycemic diabetic ketoacidosis (euDKA), a rare but serious complication where ketoacidosis occurs with blood glucose levels lower than typically seen in classic DKA presentations. 1, 2, 3, 2, 1
Mechanism and Incidence
SGLT-2 inhibitors cause euDKA through multiple mechanisms 1:
- Enhanced glycosuria (eliminating 60-100g glucose/day)
- Increased lipolysis and hyperglucagonemia driving gluconeogenesis
- Decreased urinary excretion of ketone bodies
- Dose-dependent medication effects
The incidence is approximately 0.1% among patients with diabetes taking SGLT-2 inhibitors 4, 5, though this represents a significantly elevated risk compared to other antidiabetic classes.
Key Risk Factors to Identify
Patients at highest risk include those with 1, 2, 1:
- Insulin deficiency states (including undiagnosed late-onset type 1 diabetes, which comprises 5-10% of adult-onset diabetes)
- Metabolically stressful events: surgery, trauma, prolonged fasting, acute illness
- Missed insulin doses or substantial insulin reductions (>20% decrease)
- Alcohol abuse
- Volume depletion
- Very low-carbohydrate/ketogenic diets (daily carbohydrate intake may be less than the 60-100g eliminated by SGLT-2 inhibitors)
- Complex insulin regimens or labile glucose control
Clinical Presentation
EuDKA presents with plasma glucose that may be only mildly elevated (often <14 mmol/L or 250 mg/dL), making diagnosis challenging 2, 3. Symptoms include 2, 5:
- Nausea and vomiting
- Abdominal pain
- Generalized weakness and lethargy
- Shortness of breath
- Confusion
- Excessive thirst
Comparison with Other Antidiabetic Classes
Sulfonylureas are primarily associated with hypoglycemia, not ketoacidosis 2, 6. They are considered among the least desirable alternatives due to hypoglycemia risk but do not cause euDKA.
DPP-4 inhibitors have minimal association with ketoacidosis. Their main concerns are potential increased heart failure hospitalizations with saxagliptin and alogliptin 7, not metabolic acidosis.
GLP-1 receptor agonists showed increased hyperglycemia with ketosis in one trial (liraglutide at 1.8mg/day dose was 2.2 times more likely than placebo) 3, but this is substantially less than the established risk with SGLT-2 inhibitors and is not a characteristic class effect across multiple guidelines.
Critical Management Principles
- Avoid substantial insulin dose reductions (>20%) when initiating SGLT-2 inhibitors
- Implement "sick day" management: temporarily discontinue SGLT-2 inhibitors during dehydrating illness, surgery, or prolonged fasting
- Exercise caution in patients on very low-carbohydrate diets
- Initiate with specialist collaboration in patients with complex insulin regimens or labile glucose
Patient education must include 2, 5:
- Recognition of euDKA symptoms (especially that they can occur with near-normal glucose)
- Instructions to seek immediate medical care if symptoms develop
- Clear sick day rules for medication discontinuation
Common Pitfall
The most dangerous pitfall is delayed diagnosis due to normal or only modestly elevated blood glucose levels 2, 3. Clinicians must maintain high suspicion for euDKA in SGLT-2 inhibitor users presenting with acidosis symptoms, even when glucose appears reassuring. Always check serum ketones (β-hydroxybutyrate preferred) rather than relying solely on glucose levels.